Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00330954 · ClinicalTrials.gov registry record

Gene Expression Profiling in Type 1 Diabetes

A clinical trial of Type 1 Diabetes Mellitus, sponsored by Children's Mercy Hospital Kansas City.

Completed
Registry status
64
Enrollment target
1
Study location

NCT00330954: Completed study of Type 1 Diabetes Mellitus, sponsored by Children's Mercy Hospital Kansas City.

NCT00330954 is a study of Type 1 Diabetes Mellitus that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 64 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00330954, a study of Type 1 Diabetes Mellitus, has completed, sponsored by Children's Mercy Hospital Kansas City.

COMPLETED
Registry status
64 participants
Enrollment target
1
Study location

Study Summary

One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease. Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.

Conditions Studied

Study Locations (1)

Missouri

  • Children's Mercy Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2006-06
Est. Completion 2008-04

What the finished NCT00330954 record still lists

NCT00330954 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.

NCT00330954 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT00330954 about?

NCT00330954 is a clinical study titled "Gene Expression Profiling in Type 1 Diabetes". One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitori...

What is the current status of trial NCT00330954?

This trial is currently completed. The enrollment target is 64 participants. The study started on 2006-06. Estimated completion is 2008-04.

What conditions does trial NCT00330954 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

Who is sponsoring clinical trial NCT00330954?

This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00330954 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00330954's enrollment target sits among peer trials

64 42nd of 112 higher than 71 of 112 other Type 1 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00330954, the US trial registry maintained by the National Library of Medicine. NCT00330954 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.